Pulmonary arterial hypertension (PAH) is a heterogenic diagnosis including idiopathic and hereditary PAH (IPAH/HPAH) and groups associated to connective tissue disease (APAH-CTD) and congenital heart disease (APAH-CHD). Pre- and post-diagnosis societal costs in PAH subgroups are not well known.
Several disease related factors of pulmonary hypertension (PH) can negatively impact the nutritional status, leading to an increased risk of malnutrition. However, there are no studies on the best method for nutritional screening in PH patients.
Prognostic markers of Group 3 pulmonary hypertension (PH) remain largely unknown. In this study, we evaluate clinical data to provide a comprehensive profile of patients with Group 3 PH and evaluate the potential use of vasoreactivity testing as a prognostic tool within this population.
A meaningful number of patients with PAH die suddenly, and there is little data to understand the events surrounding sudden death in PAH. We tested the hypothesis that sudden death is associated with pre-mortem ECG or hemodynamics changes compared to those who died of RHF.
ACE2 has shown effectiveness in treating pulmonary hypertension in multiple animal models and has some promise in early human trials. The key barrier to translation is that enzymatically active ACE2 is difficult to manufacture and exhibits a short half-life in humans, making chronic administration challenging.
Reduced functional capacity and poor sleep quality are common in pulmonary arterial hypertension (PAH). Wearable devices are an emerging, user-friendly tool to capture activity and sleep information. We aimed to determine whether Fitbit-derived activity and sleep trends provide clinically meaningful information in patients with PAH.
Kholdani and colleagues describe patient characteristics, completeness of diagnostic testing, treatment patterns, risk characteristics, and outcomes of a large cohort of patients with pulmonary arterial hypertension seen at an academic pulmonary hypertension center over a 20-year period.
Pulmonary hypertension (PH) at high altitudes presents unique characteristics due to hypobaric hypoxia. We aimed to evaluate the association between early diagnosis and clinical outcomes among children with severe PH living at high altitudes. A retrospective analysis was conducted on 86 children, divided into three age groups at the time of diagnosis: ≤3, 3–10, and ≥10 years.
Ventricular septal defect (VSD) is one of the most common congenital heart defects. Large, uncorrected VSDs can lead to significant left-to-right shunting, resulting in pulmonary arterial hypertension (PAH) and progressive pulmonary vascular disease. Early surgical intervention is recommended but is not always possible due to various socioeconomic and health infrastructure-related issues, especially in countries like India.
